Tesaro courted by big pharma

Reuters reported that US-based biotech group Tesaro is weighing bids and expressions of acquisition interest for the Waltham, Massachusetts-based company. Tesaro’s key asset is probably Niraparib, which targets solid tumors in ovarian and breast cancers, currently undergoing a clinical trial whose results are expected before the end of the year. Niraparib is a PARP inhibitor with potential sales of over $3bn. Tesaro’s shares rose 17% soon after the news started circulating. Importantly, Tesaro entered into an agreement with Merck & Co, aimed at studying the interaction between Niraparib and Keytruda, in 2016. (Source Reuters)